XmAbCD40 improves survival of mice bearing disseminated Ramos lymphoma. Ramos cells (5 × 10⁶) were injected intravenously into SCID mice. Starting 3 days later, 0.6, 2, or 6 mg/kg XmAbCD40, XmAb isotype control, or vehicle (PBS) was administered intraperitoneally twice per week for a total of 5 injections, as indicated by arrows (n = 10/group). XmAbCD40 significantly enhances survival at all doses relative to both vehicle and isotype controls (P < .0001); 80% of the 0.6-mg/kg group and 90% of the 2-mg/kg and 6-mg/kg groups continued to survive at study end (day 60), whereas all the control mice had died by day 28.